<DOC>
	<DOCNO>NCT01121575</DOCNO>
	<brief_summary>Lung cancer tumor become resistant first generation epidermal growth factor receptor ( EGFR ) inhibitor erlotinib gefitinib change increase activity two cell signal pathway : cMET pathway EGFR pathway . Both resistance mechanism occur time , patient even tumor . This study combine second generation EGFR inhibitor cMET inhibitor block pathway order overcome resistance treat disease .</brief_summary>
	<brief_title>A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor ( PF-02341066 And PF-00299804 ) In Patients With Non- Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>advanced non small cell lung cancer ( dose escalation phase ) acquire resistance erlotinib gefitinib ( expansion phase ) mandatory entrance biopsy ( expansion phase ) interstitial lung disease unstable brain metastasis leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Phase 1 acquire resistance erlotinib gefitinib cMET inhibitor EGFR inhibitor panHER inhibitor combination trial Crizotinib</keyword>
</DOC>